VoyForums
[ Show ]
Support VoyForums
[ Shrink ]
VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2, 3, [4], 5 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 21:25:57 08/04/06 Fri
Author: The Website for the Pharmaceutical Industry
Subject: Daiichi Pharmaceutical Company Pharmaceutical Plant, Beijing, China
In reply to: Daiichi Pharmaceutical Co., Ltd. 's message, "Hoover's coverage by Rachel Meyer" on 06:06:09 08/04/06 Fri

Daiichi Pharmaceutical Company Pharmaceutical Plant, Beijing, China
Daiichi Pharmaceutical Company Ltd completed a pharmaceutical plant at Beijing on June 6 2000. The facility is located in the Beijing economic and technological development area in China.

Daiichi Pharmaceuticals is a large Japanese manufacturer of prescription medicines in Japan. The company's product lines include treatments for infections, cancer, cardiovascular problem and intestinal disorders.

DAIICHI PHARMACEUTICAL (BEIJING) COMPANY
Daiichi Pharmaceutical established Daiichi Pharmaceutical (China) Company Ltd (DPB) in November 1995 as a wholly owned subsidiary. Since then, DPB has been acting as a sales office for Daiichi Pharmaceutical exports to China. In May 1998, Daiichi Pharmaceutical and Beijing Pharmaceutical Group Company Ltd. (formerly called Beijing General Pharmaceutical Corporation) established a joint venture company called Daiichi Pharmaceutical (Beijing) Company Ltd. (DPP) to manufacture as well as sell drugs in China. Along with DPB's original development and medical information functions, the new plant gives Daiichi Pharmaceutical an integrated Chinese base for development, production and sales.

PLANT CONSTRUCTION TIMESCALE
DPP began constructing the pharmaceutical factory in the Beijing Economic Technological Development Area in October 1998. The project was completed on June 6 2000, with the construction of an office and quality control building, solid-pharmaceutical facilities, warehouse and engineering buildings. In addition to the current solid pharmaceutical production line, Daiichi plans to complete a new production line for injectable pharmaceuticals of plastic bottle packages by March 2002.

TABLETS AND INJECTION
The main products manufactured in the plant are the antibacterial agent's Cravit tablets and Translon tablets, Tarivid tablets, and Cravit injection. For the production phase, Daiichi has strengthened its quality assurance systems and reduced product defects through the methodical introduction of good manufacturing practices (GMP) procedures devised in-house.

To increase manufacturing efficiency, the factories of all Daiichi Group companies are working to sharpen their focus on technological fields in which they are particularly proficient and shift operations involving other technologies to the Group factories that are best positioned to handle them. The company has also created a unified information management system for all its factories and R&D facilities and steadily increased the number and upgraded the qualifications of factories' technical and quality assurance specialists. The Daiichi Group has built a manufacturing system that is compliant with international quality assurance standards to ensure a cost efficient, stable supply of all the company's products, from prescription drugs to diagnostic reagents.

THE PLANT
The site of the plant extension is 47,800 square metres. The building space is 6,900 square metres and the floor space is 11,400 square metres. The facilities built comprise an administrative/quality control building, solid pharmaceutical production, injectable pharmaceutical production, warehouse, engineering buildings, and utility facilities.

The plant capacity for solid pharmaceuticals is for 200 million tablets/year (film coating tablets, plain tablets). In addition to the current solid pharmaceutical production line, Daiichi plans to complete a new production line for injectable pharmaceuticals of plastic bottle packages by March 2002. The injection production capacity is of (plastic bottle packages) 2 million bottles/year. Equipped with production equipment and quality control systems, DPB plans to start sales of its first locally produced product, Cravit tablets, in 2001.

The new plant should allow Daiichi to achieve consolidated sales in China in the range of $90 million by 2004. The total investment in the plant is approximately of $65.5 million.

Click here for printable version


SPECIFICATIONS
Website - http://www.pharmaceutical-technology.com/projects/daiichi/

[ Next Thread | Previous Thread | Next Message | Previous Message ]
[ Contact Forum Admin ]

Forum timezone: GMT-8
VF Version: 3.00b, ConfDB:
Before posting please read our privacy policy.
VoyForums(tm) is a Free Service from Voyager Info-Systems.
Copyright © 1998-2019 Voyager Info-Systems. All Rights Reserved.